Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria-Reference-Cited by-同舟云学术

Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria

Published:2010-05 Issue:3 Volume:149 Page:414-425
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Hill Anita,Rother Russell P.,Wang Xunde,Morris, Jr Sidney M.,Quinn-Senger Kerry,Kelly Richard,Richards Stephen J.,Bessler Monica,Bell Leonard,Hillmen Peter,Gladwin Mark T.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2010.08096.x/fullpdf

Reference59 articles.

1. Gastrointestinal involvement in paroxysmal nocturnal hemoglobinuria: first report of electron microscopic findings;Adams;Digestive Diseases and Sciences,2002

2. Cardiac involvement in thalassemia intermedia: a multicenter study;Aessopos;Blood,2001

3. Sickle cell disease and pulmonary hypertension in Africa: a global perspective and review of epidemiology, pathophysiology, and management;Aliyu;American Journal of Hematology,2008

4. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension;Andreassen;American Journal of Cardiology,2006

5. Arginase activity in erythrocytes of healthy and ill children;Azizi;Clinical Chimica Acta,1970

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Three Years On: The Role of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) since Its Initial Approval;International Journal of Molecular Sciences;2024-08-09

2. Group 5 Pulmonary Hypertension: Multiple Systemic Diseases, Multiple Mechanisms of Pulmonary Hypertension, and Multiple Management Challenges;Current Respiratory Medicine Reviews;2024-08

3. Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab;European Journal of Clinical Pharmacology;2024-05-30

5. Fatigue Item Response among Hemoglobin-Normalized Patients with Paroxysmal Nocturnal Hemoglobinuria: PEGASUS Trial Results at 16 and 48 Weeks;Journal of Clinical Medicine;2024-03-15